{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T01:08:40Z","timestamp":1780794520526,"version":"3.54.1"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"44","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>The treatment of metastatic melanoma has been revolutionized in the past decade because of the development of immunotherapies and targeted therapies. Despite these developments, there is still an unmet clinical need for more advanced combination therapies for the subset of patients who remain resistant to immunotherapy or targeted therapy alone. To our knowledge, no reports have been published on combinations of PD-1 blockades and c-KIT inhibitors in melanoma patients. Furthermore, data are limited regarding the safety and efficacy of this combination in patients harboring KIT mutations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns and diagnosis:<\/jats:title>\n            <jats:p>We report a case of an 82-year-old female with metastatic melanoma who was found to have double KIT mutations at V559 and N822I.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>She was treated with a combination of c-KIT inhibitor and PD-1 blockade after being resistant to anti-PD-1 monotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>Patient developed two episodes of grade 2 liver toxicity requiring treatment breaks followed by a dose reduction. Her transaminitis eventually resolved and patient remained on combination treatment for almost two years with good control of her disease prior to progression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Treatment options for patients who progress after PD-1 inhibitors are very limited; therefore, there is a high unmet clinical need for this patient population. Combining Imatinib with checkpoint inhibitors may be efficacious in patients with metastatic melanoma and KIT mutations. This novel combination can cause additional toxicities which seem to be overall manageable.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000017769","type":"journal-article","created":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T19:38:47Z","timestamp":1572896327000},"page":"e17769","source":"Crossref","is-referenced-by-count":13,"title":["Combination of pembrolizumab and imatinib in a patient with double KIT mutant melanoma"],"prefix":"10.1097","volume":"98","author":[{"given":"Yara","family":"Abdou","sequence":"first","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center, Buffalo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankita","family":"Kapoor","sequence":"additional","affiliation":[{"name":"Rochester General Hospital, Rochester, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamya","family":"Hamad","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center, Buffalo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Ernstoff","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center, Buffalo"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,11]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2217\/fon-2018-0607","article-title":"Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma","volume":"15","author":"Carreau","year":"2019","journal-title":"Future Oncol"},{"issue":"(1A)","key":"R2-20230915","first-page":"68","article-title":"BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients","volume":"22","author":"Mackiewicz","year":"2018","journal-title":"Contemp Oncol (Pozn)"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1200\/JCO.2006.06.2984","article-title":"Somatic activation of KIT in distinct subtypes of melanoma","volume":"24","author":"Curtin","year":"2006","journal-title":"J Clin Oncol"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1200\/JCO.2012.47.7836","article-title":"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin","volume":"31","author":"Hodi","year":"2013","journal-title":"J Clin Oncol"},{"key":"R5-20230915","first-page":"966","article-title":"Development of immune checkpoint inhibitors","volume":"58","author":"Kitano","year":"2017","journal-title":"Rinsho Ketsueki"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/CMR.0000000000000444","article-title":"Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors","volume":"28","author":"Chesney","year":"2018","journal-title":"Melanoma Res"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.2147\/DDDT.S89114","article-title":"Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells","volume":"10","author":"Abbaspour Babaei","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"7726","DOI":"10.1158\/1078-0432.CCR-08-1144","article-title":"Imatinib targeting of KIT-mutant oncoprotein in melanoma","volume":"14","author":"Jiang","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/j.1755-148X.2010.00822.x","article-title":"V559A and N822I double KIT mutant melanoma with predictable response to imatinib?","volume":"24","author":"McDonnell","year":"2011","journal-title":"Pigment Cell Melanoma Res"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1158\/1078-0432.CCR-16-1163","article-title":"PD-1\/PD-L1 Blockade Enhances T-cell activity and antitumor efficacy of imatinib in gastrointestinal stromal tumors","volume":"23","author":"Seifert","year":"2017","journal-title":"Clin Cancer Res"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"e1101207","DOI":"10.1080\/2162402X.2015.1101207","article-title":"Vemurafenib and ipilimumab: a promising combination? Results of a case series","volume":"5","author":"Hassel","year":"2016","journal-title":"Oncoimmunology"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1053\/j.seminoncol.2015.09.030","article-title":"Tyrosine kinase inhibitors early in the disease course: lessons from chronic myelogenous leukemia","volume":"42","author":"Yilmaz","year":"2015","journal-title":"Semin Oncol"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3727\/096504018X15331163433914","article-title":"Efficacy evaluation of imatinib for the treatment of melanoma: evidence from a retrospective study","volume":"27","author":"Wei","year":"2019","journal-title":"Oncol Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000017769","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T00:39:15Z","timestamp":1694824755000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000017769"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":13,"journal-issue":{"issue":"44","published-online":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000017769","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11]]}}}